A Case of M-Paraprotein-Associated Polyneuropathy with Stable Response to Rituximab Therapy

Monoclonal gammopathy of undetermined significance is diagnosed on the basis of an extensive search for a diagnostic reason as paraprotein secretion occurs in different diseases. One of polyneuropathies associated with M-paraproteinemia is anti-MAG demyelinating polyneuropathy (AMDP). The first-line treatment of this disease is based on prednisolone, and intravenous immunoglobulin. The second-line therapy of treatment-resistant patients is not determined. We report a case of a female patient with AMDP who received prednisolone, azathioprine, and plasmapheresis; however, stable response was reached only after the use of rituximab.

• Vsevolod Gennad’evich Potapenko Municipal Clinical Hospital No. 31, 3 Dinamo pr-t, Saint Petersburg, Russian Federation, 197110; IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022 ; ГБУЗ «Городская клиническая больница № 31», пр-т Динамо, д. 3, Санкт-Петербург, Российская Федерация, 197110; ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, ул. Льва Толстого, д. 6/8, Санкт-Петербург, Российская Федерация, 197022
• V.N. Kiselev AM Nikiforov Russian Center of Emergency and Radiation Medicine, 4/2 Akademika Lebedeva str., Saint Petersburg, Russian Federation, 194044 ; ФГБУ «Всероссийский центр экстренной и радиационной медицины им. А.М. Никифорова» МЧС России, ул. Академика Лебедева 4/2, Санкт-Петербург, Российская Федерация, 194044

1. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564–9. doi: 10.1056/NEJMoa01133202. DOI: https://doi.org/10.1056/NEJMoa01133202
2. Гинзберг М.А., Варламова Е.Ю., Рыжко В.В. и др. Клинико-нейрофизиологическое исследование хронической демиелинизирующей полиневропатии, ассоциированной с моноклональной секрецией. Медицинский совет. 2015;10:93–6.
3. [Ginzberg MA, Varlamova EYu, Ryzhko VV, et al. Clinical and neurophysiological study of chronic demyelinating polyneuropathy associated with monoclonal secretion. Meditsinskii sovet. 2015;10:93–6. (In Russ)]
4. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – First Revision. J Peripher Nerv Syst. 2010;15(1):1–9. doi: 10.1111/j.1529-8027.2010.00245.x. DOI: https://doi.org/10.1111/j.1529-8027.2010.00245.x
5. Dalakas MC, Rakocevic G, Salajegheh M. Placebo-controlled trial of rituximab in IgM anti-myelin associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009;65(3):286–93. doi: 10.1002/ana.21577. DOI: https://doi.org/10.1002/ana.21577
6. Супонева Н.А., Павлов Э.В. Диагностика и базовая терапия хронических полиневропатий. Врач. 2009;4:43–4.
7. [Suponeva NA, Pavlov EV. Diagnosis and basic therapy of chronic polyneuropathies. Vrach. 2009;4:43–4. (In Russ)]
8. Яковлев А.А., Гапешин Р.А., Смочилин А.Г., Яковлева М.В. Оценка эффективности человеческого иммуноглобулина у пациентов с полинейропатией, ассоциированной с моноклональной гаммапатией неустановленной этиологии. Архивъ внутренней медицины. 2018;8(4):278–84. doi: 10.20514/2226-6704-2018-8-4-278-284. DOI: https://doi.org/10.20514/2226-6704-2018-8-4-278-284
9. [Yakovlev AA, Gapeshin RA, Smochilin AG, Yakovleva MV. Evaluation of human immunoglobulin effectiveness in patients with sensorymotor polyneuropathy associated with monoclonal gammapathy of undetermined significance. The Russian Archives of Internal Medicine. 2018;8(4):278–84. doi: 10.20514/2226-6704-2018-8-4-278-284. (In Russ)] DOI: https://doi.org/10.20514/2226-6704-2018-8-4-278-284
10. Comi G, Roveri L, Swan A, et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol. 2002;249(10):1370–7. doi: 10.1007/s00415-002-0808-z. DOI: https://doi.org/10.1007/s00415-002-0808-z
11. Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2006;2:CD002827. doi: 10.1002/14651858.cd002827.pub2. DOI: https://doi.org/10.1002/14651858.CD002827.pub2
12. Leger JM, Viala K, Nicolas G, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology. 2013;80(24):2217–25. doi: 10.1212/WNL.0b013e318296e92b. DOI: https://doi.org/10.1212/WNL.0b013e318296e92b
13. Gazzola S, Delmont E, Franques J, et al. Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy. J Neurol Sci. 2017;377:144–8. doi: 10.1016/j.jns.2017.04.015. DOI: https://doi.org/10.1016/j.jns.2017.04.015
14. Niermeijer JMF, Fischer K, Eurelings M, et al. Prognosis of polyneuropathy due to IgM monoclonal gammopathy: a prospective cohort study. Neurology. 2010;74(5):406–12. doi: 10.1212/wnl.0b013e3181ccc6b9. DOI: https://doi.org/10.1212/WNL.0b013e3181ccc6b9
15. Nobile-Orazio E, Meucci N, Baldini L, et al. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain. 2000;123(4):710–7. doi: 10.1093/brain/123.4.710. DOI: https://doi.org/10.1093/brain/123.4.710
16. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572–81. doi: 10.1056/nejmoa032534. DOI: https://doi.org/10.1056/NEJMoa032534